Preliminary safety and efficacy report of a randomized trial of alemtuzumab vs chlorambucil as front-line therapy in 297 patients with progressive B-cell chronic lymphocytic leukemia.

被引：2
|
作者：
Hillmen, P
Skotnicki, AB
Robak, T
Mayer, J
Jaksic, B
Vukovic, V
Weitman, S
机构：
[1] Leeds Gen Infirm, PL-90131 Wakefield, England
[2] Jagiellonian Univ, Krakow, Poland
[3] Med Univ Lodz, Lodz, Poland
[4] Univ Hosp Brno, Brno, Czech Republic
[5] Univ Zagreb, Clin Hosp Merkur, Zagreb, Croatia
[6] Ilex Pharmaceut LP, San Antonio, TX USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.2505.2505
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2505
引用
收藏
页码：687A / 687A
页数：1
相关论文
共 50 条
  • [11] Chlorambucil PLUS Rituximab As FRONT-LINE THERAPY in Elderly or Unfit Patients Affected by B-CELL Chronic Lymphocytic Leukemia: Results of A Single-Centre Retrospective Analysis
    Laurenti, Luca
    Vannata, Barbara
    Innocenti, Idanna
    Autore, Francesco
    Santini, Francesco
    Sora, Federica
    Za, Tommaso
    Marietti, Sara
    Bellesi, Silvia
    Sica, Simona
    Efremov, Dimitar G.
    Leone, Giuseppe
    BLOOD, 2012, 120 (21)
  • [12] Combined schedule of fludarabine and alemtuzumab followed by maintenance with low-dose alemtuzumab is effective for patients with progressive B-cell chronic lymphocytic leukemia.
    Kowal, M
    Nowak, W
    Nowaczynska, A
    Dmoszynska, A
    Skotnicki, AB
    BLOOD, 2005, 106 (11) : 343B - 344B
  • [13] Alemtuzumab is effective in the treatment of patients with advanced, heavily pretreated B-cell chronic lymphocytic leukemia.
    Fiegl, M
    Hopfinger, G
    Jaeger, G
    Fridrik, M
    Zojer, N
    Walla, B
    Andel, J
    Schmid, FX
    Weisz, H
    Mayer, P
    Buchel, J
    Greil, R
    BLOOD, 2003, 102 (11) : 358B - 358B
  • [14] Incidence of genomic aberrations and associated efficacy from a phase III study comparing alemtuzumab (CAMPATH®, MABCAMPATH®) vs chlorambucil as first line therapy for B-cell chronic lymphocytic leukemia (BCLL).
    Robak, Tadeusz
    Dmoszynska, Anna
    Fetni, Raouf
    Wang, Ying
    Belkacz, Malika
    Sirard, Cynthia
    Goldberg, Mark
    Skotnicki, Aleksander
    Mayer, Jiri
    Hillmen, Peter
    BLOOD, 2006, 108 (11) : 593A - 593A
  • [15] Efficacy and safety of alemtuzumab in patients with relapsed B-cell chronic lymphocytic leukemia after autologous stem cell transplantation.
    Dartigeas, C
    Degenne, M
    Senecal, D
    Roingeard, P
    Cendrie, C
    Delain, M
    Benboubker, L
    Linassier, C
    Watier, H
    Binet, C
    Colombat, P
    Cartron, G
    BLOOD, 2004, 104 (11) : 688A - 688A
  • [16] Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients
    Fiegl, Michael
    Falkner, Florian
    Steurer, Michael
    Zojer, Niklas
    Hopfinger, Georg
    Haslbauer, Ferdinand
    Winder, Guntram
    Voskova, Daniela
    Andel, Johannes
    Lang, Alois
    Brychtova, Yvona
    Mayer, Jiri
    Greil, Richard
    Gastl, Guenther
    ANNALS OF HEMATOLOGY, 2011, 90 (09) : 1083 - 1091
  • [17] Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients
    Michael Fiegl
    Florian Falkner
    Michael Steurer
    Niklas Zojer
    Georg Hopfinger
    Ferdinand Haslbauer
    Guntram Winder
    Daniela Voskova
    Johannes Andel
    Alois Lang
    Yvona Brychtova
    Jiri Mayer
    Richard Greil
    Günther Gastl
    Annals of Hematology, 2011, 90 : 1083 - 1091
  • [18] EFFICACY AND SAFETY OF FLUDARABINE AND CYCLOPHOSPHAMIDE REGIME AS FRONT-LINE THERAPY IN PATIENTS AFFECTED BY CHRONIC LYMPHOCYTIC LEUKEMIA WITH LOW RISK BIOLOGICAL PARAMETERS
    Laurenti, L.
    Laurenti, L.
    De Padua, L.
    Tarnani, M.
    Piccirillo, N.
    Falcucci, P.
    D'Arena, G.
    Innocenti, I.
    Marietti, S.
    Efremov, D.
    Chiusolo, P.
    Zini, G.
    Rumi, C.
    Sica, S.
    Leone, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 524 - 525
  • [19] Response to fludarabine in B-cell chronic lymphocytic leukemia patients previously treated with chlorambucil as up-front therapy and a CHOP-like regimen as second line therapy
    Liso, V
    Molica, S
    Capalbo, S
    Pogliani, E
    Battista, C
    Broccia, G
    Montillo, M
    Cuneo, A
    Leoni, P
    Specchia, G
    Castoldi, G
    HAEMATOLOGICA, 2001, 86 (11) : 1165 - 1171
  • [20] Campath-1-h therapy of patients with advanced B-cell chronic lymphocytic leukemia.
    Mahe, B
    Gueglio, B
    Morineau, N
    Vigier, M
    Moreau, P
    Chevallier, P
    Milpied, NJ
    Harousseau, JL
    BLOOD, 2002, 100 (11) : 361B - 361B
12345